AzTrials
AzTrials

SchizophreniaPhase 3NCT01914393

Pediatric Open-Label Extension Study

A Phase 3 study testing Lurasidone 20, 40, 60, 80 mg, flexibly dosed in people with Schizophrenia and Autism, run by Sumitomo Pharma America, Inc. at 88 sites in 15 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the preceding studies, D1050301, D1050325, and D1050326 Read more about this study

Who is it for?
Ages 6 to 17 years
Conditions the study is for
Schizophrenia, Autism, Bipolar Depression
What is being tested?
Lurasidone 20, 40, 60, 80 mg, flexibly dosed
Could I receive a placebo?
No, everyone receives an active treatment
How many people
702 participants
Where
88 sitesin 15 countries
Study dates
30 Sep 2013to 17 Oct 2018
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Written informed consent from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects' participation in the study procedures must be obtained for subjects who are not emancipated. In accordance with Institutional Review Board (IRB) or Independent Ethics Committee (IEC) requirements, the subject will complete an informed assent when developmentally appropriate, to participate in the study before conduct of any study-specific procedures.
  • Subject has completed Study D1050301 (Visit 9) OR
  • Subject has completed Study D1050325 (Visit 9) OR
  • Subject has completed Study D1050326 (Visit 8)
  • Subject is judged by the investigator to be appropriate for participation in a 104-week clinical trial in an outpatient setting involving open-label lurasidone treatment, and is able to comply with the protocol.
  • A reliable informant (eg, parent, legal guardian, or caregiver) must be available to accompany the subject at each visit. For subjects entering from Study D1050325, the reliable caregiver must also oversee the administration of the study drug throughout the study
Show all 11Show fewer
  • Females who participate in this study:
  • are unable to become pregnant (eg, premenarchal, surgically sterile, etc.) -OR-
  • practices true abstinence (consistent with lifestyle) and must agree to remain abstinent from signing informed consent to at least 7 days after the last dose of study drug has been taken; -OR-
  • are sexually active and willing to use a medically effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.
  • Males must be willing to remain sexually abstinent (consistent with lifestyle) or use an effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.

Who cannot join

  • Subject is considered by the investigator to be at imminent risk of suicide.
  • Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive dyskinesia, or any other moderate or severe movement disorder. Severity to be determined by the investigator.

Trial locations and contacts

88 sites in 15 countries.

88 sites in 15 countries

United States35 sites
  • Atlanta Center for Medical Research

    Atlanta, Georgia, 30308

  • Kennedy Krieger Institute

    Baltimore, Maryland, 21205

  • Neurobehavioral medicine Group, LLC

    Bloomfield Hills, Michigan, 48302

  • University of Virginia

    Charlottesville, Virginia, 22903

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, 45219

  • University Hospitals Case Medical Center

    Cleveland, Ohio, 44106

  • Ericksen Research & Development, LLC

    Clinton, Utah, 84015

  • The Ohio State University Nisonger Center

    Columbus, Ohio, 43210

  • Pillar Clinical Research, LLC

    Dallas, Texas, 75243

  • Harmonex Neuroscience Research

    Dothan, Alabama, 36303

  • Diligent Clinical Trials, Inc

    Downey, California, 90241

  • Sarkis Clinical Trials - Parent

    Gainesville, Florida, 32607

  • North Shore/Long Island Jewish PRIME

    Glen Oaks, New York, 11004

  • Neuroscience, Inc.

    Herndon, Virginia, 20170

  • Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340

    Lake Charles, Louisiana, 70601

  • University Of Kentucky

    Lexington, Kentucky, 40509

  • Dr. Jeanette Cueva

    Mount Kisco, New York, 10549

  • Jersey Shore University Medical Center

    Neptune City, New Jersey, 07753

  • Montefiore Medical Center PRIME

    New York, New York, 10467

  • Cutting Edge Research Group

    Oklahoma City, Oklahoma, 73116

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida, 32801

  • APG Research, LLC

    Orlando, Florida, 32803

  • Psychiatric Associates

    Overland Park, Kansas, 66211

  • Clinical Research Partners, LLC

    Petersburg, Virginia, 23805

  • Carilion Clinic

    Roanoke, Virginia, 24014

  • Finger Lakes Clinical Research

    Rochester, New York, 10618

  • St. Charles Psychiatric Associates

    Saint Charles, Missouri, 63301

  • University of California San Francisco Medical Center

    San Francisco, California, 94143

  • Medical Research Group of Central Florida

    Sanford, Florida, 32771

  • Neuropsychiatric Research Center of Orange County

    Santa Ana, California, 92701

  • Attalla Consultants, LLC

    Smyrna, Georgia, 30080

  • University of South Florida

    St. Petersburg, Florida, 33701

  • Richmond Behavioral Associates

    Staten Island, New York, 10312

  • University of South Florida Rothman Center of Neuropychiatry

    Tampa, Florida, 33613

  • Family Psychiatry of The Woodlands, P.A.

    The Woodlands, Texas, 77381

Other trials in United States

Russia11 sites
  • GUZ Lipetsk Regional psychoneurological Hospital #1

    Lipetsk, 399313

  • Closed corporation "Scientific Center of Personalized Psychiatry"

    Moscow, 119180

  • Scientific Center of Personalized Psychiatry

    Moscow, 119180

  • State Healthcare Institution of Nizhniy Novgordo region "Clinical Psychiatric Hospital #1 of City of Nizhniy Novgorod"

    Nizhny Novgorod, 603155

  • SHI "City Psychoneurological dispensary #7 (with Hospital)"

    Saint Petersburg, 190005

  • Center of Recovery Treatment "Pediatric Psychiatry" named after S.S. Mnukhin

    Saint Petersburg, 197022

  • Bekhterev Institute

    Saint Petersburg

  • Regional Clinical Mental Hospital of Saint Sofiya

    Saratov, 410060

  • FSBSI "Scientific Research Institute of Mental Health"

    Tomsk, 634014

  • State Healthcare Institution of Yaroslavl Rgion "Yaroslavl Regional clinical Mental Hospital"

    Yaroslavl, 150003

  • Sverdiovsk Regional Clinical Psychiatric Hospital

    Yekaterinburg, 62003

Other trials in Russia

Ukraine10 sites
  • RPsH #3 Сhildren Dept SHEI Ivano-Frankivsk SMU

    Ivano-Frankivsk, 76014

  • SI Institute of Neurology, Psychiatry and Narcology of NAMSU

    Kharkiv, 61068

  • SI Institute of Children and Adolescents Healthcare of NAMSU

    Kharkiv, 61153

  • TMA Psychiatry in Kyiv Center of NT & Rehabilitation of Psychotic Conditions

    Kyiv, 04080

  • CI Lviv Regional Clinical Psychiatric Hospital

    Lviv, 79021

  • Odesa Regional Psychoneurological Dispensary, Outpatient Dept.

    Odesa, 65014

  • O.F. Maltcev Poltava RCPsH Children Dept Ukrainian Medical Stomatological Academy

    Poltava, 36006

  • CI Kherson Regional Psychiatric Hospital of Kherson RC

    Stepanovka, 73488

  • Ternopil RCCPH Dept of Psychiatry #9 (adolescent)& #8 (pediatric) Ternopil I.Ya. Gorbachevskyi SMU

    Ternopil, 46020

  • Reg. Psych. Hosp.n.a. O.Yuschenko, Dept. #121 VNMI

    Vinnitsia, 21018

Other trials in Ukraine

Mexico6 sites
  • Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C.

    Culiacán, Sinaloa, 80020

  • Dr. Jessica Rosas Escobar

    Durango, 34000

  • Instituto de Investigaciones Aplicadas a la Neurociencia A.C.

    Durango, 34000

  • Accelerium S. de R.L. de C.V.

    Monterrey, 64000

  • Instituto de Informacion de Investigacion en Salud Mental

    Monterrey, 64710

  • Av Modesto Arreola #917 Ote. Col Centro

    Nuevo León, 64000

Other trials in Mexico

Bulgaria4 sites
  • MHC - Ruse, EOOD

    Rousse, 7003

  • UMHAT "Alexandrovska" EAD

    Sofia, 1431

  • MHAT-Targovishte, AD

    Targovishte, 7700

  • DCC "Mladost M" - Varna, OOD

    Varna, 9020

Other trials in Bulgaria

Philippines4 sites
  • Alexian Brothers Health and Wellness Center

    Davao City, 8000

  • West Visayas State University Medical Center

    Iloilo City, 5000

  • National Center for Mental Health

    Mandaluyong, 1553

  • Veterans Memorial Medical Center

    Quezon City, 1101

Other trials in Philippines

South Korea4 sites
  • Chonnam National University Hospital

    Gwangju, 501-757

  • Inha University Hospital

    Incheon, 400-711

  • Chonbuk National University Hospital

    Jeonju, 561-712

  • Seoul National University Hospital

    Seoul, Gyeonggi-do, 110774

Other trials in South Korea

Colombia3 sites
  • Centro de Investigaciones y Proyectos en Neurociencias CIPNA

    Barranquilla

  • E.S.E. Hospital Mental de Antioquia

    Bello, 0000

  • Centro de Investigaciones del Sistema Nervioso Limitada - Grupo CISNE Ltda

    Bogotá, 00000

Other trials in Colombia

Romania3 sites
  • Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia

    Bucharest, 041914

  • Spitalul Clinic de Psihiatrie Socola

    Iași, 700282

  • Spitalul Clinic de Urgenta pentru Copii "Louis Turcanu" Timisoara

    Timișoara, 300239

Other trials in Romania

Hungary2 sites
  • Vadaskert Alapitvany a Gyermekek Lelki Egeszsegeert

    Budapest, 1021

  • Bekes Megyei Pandy Kalman Korhaz

    Gyula, 57--

Other trials in Hungary

Poland2 sites
  • NZOZ Poradnia Zdrowia Psychicznego

    Kobierzyce, 55-040

  • Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Oddzial Kliniczmy VI Psychiatrii Mlodziezy

    Torun, 87-100

Other trials in Poland

France1 site
  • CHU Nantes - Hôpital Mère-Enfant

    Nantes, 44093

Other trials in France

Malaysia1 site
  • University Malaya Medical Centre

    Kuala Lumpur, 59100

Other trials in Malaysia

Puerto Rico1 site
  • Centro de Investigacion Clinica Psiquiatrica

    Caguas, 00725

Other trials in Puerto Rico

Spain1 site
  • Hospital Marítimo de Torremolinos

    Torremolinos, Málaga, 29620

Other trials in Spain

About this study

Official title: A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects

This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the preceding studies, D1050301, D1050325, and D1050326

Being tested
Lurasidone 20, 40, 60, 80 mg, flexibly dosed
Keywords
Schizophrenia, Autism, Lurasidone, Latuda
Medical subject headings
Schizophrenia, Autistic Disorder, Bipolar Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lurasidone 20, 40, 60, 80 mg, flexibly dosedDrug

    Also called Latuda

    Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed

Study groups in NCT01914393
Study groupRoleWhat they receive
Lurasidone 20, 40, 60, 80 mg, flexibly dosedExperimentalLurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily
Receives: Drug: Lurasidone 20, 40, 60, 80 mg, flexibly dosed

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs)

    The Safety population consists of all subjects who received at least one dose of study drug in this study.

    Measured: During 104 Weeks (2-years) treatment period

Secondary outcomes (22)
  1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score

    Change from Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score for subjects continued from study D1050301.

    PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210 Higher values of PANSS total score represents greater severity of illness.

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  2. Change From Baseline in PANSS Positive Subscale Score

    Change from Baseline in PANSS Positive Subscale Score for subjects continued from study D1050301 The Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness /persecution, and hostility; Positive subscale (range 7-49) is calculated as sum of Items P1 to P7 in the positive subscale Higher values of PANSS sub-scale scores represent greater severity

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  3. Change From Baseline in PANSS Negative Subscale Score

    Change from Baseline in PANSS Negative Subscale Score for subjects continued from study D1050301 The Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; Negative subscale (range 7-49) is calculated as sum of Items N1 to N7 in the negative subscale Higher values of PANSS sub-scale scores represent greater severity of illness.

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  4. Change From Baseline in PANSS General Psychopathology Subscale Score

    Change from Baseline in PANSS General Psychopathology Subscale Score for subjects continued from study D1050301 The General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation; General psychopathology subscale (range 16-112) is calculated as sum of Items G1 to G16 in the general psychopathology subscale Higher values of PANSS sub-scale scores represent greater severity of illness.

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  5. Change From Baseline in PANSS Excitability Subscale Score

    Change from Baseline in PANSS Excitability Subscale Score for subjects continued from study D1050301 Subscale of Excitability consists of the following four items from the PANSS: excitement, hostility, uncooperativeness, and poor impulse control. The sum of the four items ranges from 4 to 28 Higher values of PANSS sub-scale scores represent greater severity of illness.

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  6. Change From Baseline in the Clinical Global Impression -Severity Score

    Change from Baseline in the Clinical Global Impression -Severity Score for subjects continued from study D1050301 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  7. Change From Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score

    Change from Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score for subjects continued from study D1050301 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  8. Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score

    Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050301

    The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows:

    % Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  9. Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Subscale Score

    Change from Baseline in ABC Irritability Subscale Score for subjects continued from study D1050325 The Aberrant Behavior Checklist (ABC) contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree).

    Irritability Subscale Score is calculated as summing of items 2, 4, 8, 10, 14, 19, 25, 29, 34, 36, 41, 47, 50, 52, and 57; as a result, ABC irritability subscale score ranges from 0 to 45.

    In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  10. Change From Baseline in Aberrant Behavior Checklist (ABC) Lethargy and Social Withdrawal Subscale Score

    Change from Baseline in ABC Lethargy and Social Withdrawal Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree).

    Lethargy and Social Withdrawal Subscale Score is calculated as summing of items 3, 5, 12, 16, 20, 23, 26, 30, 32, 37, 40, 42, 43, 53, 55, and 58. ABC Lethargy and Social Withdrawal Subscale Score ranges from 0 to 48.

    In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  11. Change From Baseline in Aberrant Behavior Checklist (ABC) Stereotypic Behavior Subscale Score

    Change from Baseline in ABC Stereotypic Behavior Subscale Score for subjects continued from study D1050325. The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Stereotypic behavior Subscale Score is calculated as summing of 6, 11, 17, 27, 35, 45, and 49 items . ABC Stereotypic behavior Subscale Score ranges from 0 to 21. Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). To score the ABC, the individual items for each subscale are simply summed to their respective totals. It is inappropriate to compute a "total aberrant score", based on a summation of all 58 items, as the subscales are largely independent. In general, higher values of ABC subscale scores represent greater severity

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  12. Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity and Noncompliance Subscale Score

    Change from Baseline in ABC Hyperactivity and Noncompliance Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree).

    Hyperactivity and noncompliance Subscale Score is calculated as summing of 1, 7, 13, 15, 18, 21, 24, 28, 31, 38, 39, 44, 48, 51, 54, and 56 items. ABC hyperactivity and noncompliance Subscale Score ranges from 0 to 48.

    In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  13. Change From Baseline in Aberrant Behavior Checklist (ABC) Inappropriate Speech Subscale Score

    Change from Baseline in ABC Inappropriate Speech Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree).

    Inappropriate speech Subscale Score is calculated as summing of 9, 22, 33, and 46 items. ABC inappropriate speech Subscale Score ranges from 0 to 12.

    In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  14. Change From Baseline in Clinical Global Impression (CGI) - Severity Score

    Change from Baseline in Clinical Global Impression (CGI) - Severity Score for subjects continued from study D1050325 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  15. Change From Baseline in Children's Yale-Brown Obsessive Compulsive Score (CY-BOCS)

    Change from Baseline in CY-BOCS for subjects continued from study D1050325 CY-BOCS used in the study is a modification of the Yale-Brown Obsessive Compulsive Scale and contains total 7 items for compulsion. "Obsessions" section was removed as it is difficult to obtain valid information given typical language/cognitive delays in the population. Each item of the compulsive scale ranges from 0 to 4. At this time, item 1b ("compulsion-free interval") and item 6 ("peculiarity of the behavior") are not being used in the scoring. Item 7 is a rating for reliability, ranging from 0 (excellent) to 3 (poor). It reflects the interview's judgment regarding the confidence in the data collected hence it is not counted in the CY-BOCS total score. The CY-BOCS compulsion total score is the sums of item 1-5. As a result, the CY-BOCS compulsion total score may range from 0 to 20. In general, higher values of CY-BOCS scores represent greater severity of illness

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  16. Change From Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score

    Change from Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score for subjects continued from study D1050325 The CGSQ is comprised of total 21 items. Each item is rated on a 5-point Likert-type scale (1 (not at all a problem) to 5 (very much a problem)) and is grouped into three subscales: objective strain, subjective externalized strain, and subjective internalized strain. The 3 subscale scores are calculated as the averages of the corresponding individual items, which range in severity from 1 to 5.

    Higher scores on each of these subscale scales indicate greater strain. A global strain score is calculated by summing the three subscales (i.e., objective strain, subjective externalized strain, and subjective internalized strain) to provide an indication of the total impact of the special demands on the family. Global strain scores range from 3 to 15. As with the individual subscales, higher scores indicate greater strain

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  17. Change From Baseline in Children's Depression Rating Scale, Revised (CDRS-R) Total Score

    Change from Baseline in CDRS-R Total Score for subjects continued from study D1050326 CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6 17 years. It contains 17 ordinally-scaled items that evaluate the presence and severity of symptoms commonly associated with depression in childhood. The CDRS-R is administered separately to the patient and to the caregiver; among 17 items, 14 items are based on separate interviews with child and parent, 3 items are based solely on the rater's observation of child (ie, no questions).The 14 items are rated on a 1 (no psychopathology) to 7 (most psychopathology) scale, where a rating of 3 represents mild psychopathology. The 3 items (sleep disturbance, appetite disturbance, listless speech) are rated on a 1 (no pathology) to 5 (most pathology) scale. The CDRS-R total score ranges from 17-113. In general, higher values of CDRS-R total score represent greater severity of illness

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  18. Change From Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score

    Change from Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score for subjects continued from study D1050326 The CGI-BP-S is a three-question clinician-rated assessment of the subject's current illness state (depression, mania, and overall) using a 7-point scale (1(normal, not ill) to 7 (very severely ill)) for each question, where a higher score is associated with greater illness severity.

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  19. Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score

    Change from Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score for subjects continued from study D1050326 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  20. Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score

    Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050326

    The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows:

    % Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  21. Change From Baseline in Pediatric Anxiety Rating Scale (PAR) Total Score

    Change from Baseline in PAR Total Score for subjects continued from study D1050326 The PARS is a clinician-rated instrument for assessing over time the severity of anxiety symptoms associated with common DSM-IV anxiety disorders in children ages 6 17 years. The PARS is administered separately to the subject and to the caregiver. The instrument has 2 sections. The first section includes a 50-item symptom checklist, which the clinician rates as present or absent during the past week. The second section is comprised of 7 severity impairment items reflecting the severity/impairment of all symptoms endorsed in Section 1 of the PARS (during the past week). Each question is answered on a 0-5 Likert scale (0 for none, and 1-5 for minimal to extreme) with alternative responses of 8=Not Applicable and 9=Does Not Know. Scores of 8 or 9 are not counted in the summation as per the PARS instructions. The PARS total score over all 7 questions ranges in value from 0 to 35.A higher PARS total score

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

  22. Change From Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score

    Change from Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score for subjects continued from study D1050326 The ADHD-RS IV is a validated scale that measures the behaviors of children with ADHD. The ADHD-RS IV consists of 18 items reflecting current symptomatology of ADHD based on DSM-IV-TR criteria. Each item is scored from a range of 0 (no symptoms) to 3 (severe symptoms) with total scores ranging from 0 to 54. The 18 items may be grouped into two sub-scales: hyperactivity/impulsivity (even number items 2 through 18) and inattentiveness (odd number items 1 through 17), ranging from 0 to 27. A higher ADHD-RS total score and sub-scales scores are associated with greater illness severity

    Measured: Open-Label Baseline, Week 28, Week 52, and Week 104

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Aug 2013 (estimated)
  2. Study start30 Sep 2013
  3. Primary completion17 Oct 2018
  4. Study completion17 Oct 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
702 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01914393
Sponsor's protocol ID
D1050302
Other IDs
2013-001694-24
Status last verified
Dec 2019
First submitted
30 Jul 2013
Last updated
19 Dec 2019
Data monitoring committee
Yes

Publications

  • DelBello MP, Tocco M, Pikalov A, Deng L, Goldman R. Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression. J Child Adolesc Psychopharmacol. 2021 Sep;31(7):494-503. doi: 10.1089/cap.2021.0040. Epub 2021 Jul 29.

    PubMed 34324397

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Lurasidone 20, 40, 60, 80 mg, flexibly dosed in people with Schizophrenia and Autism, run by Sumitomo Pharma America, Inc. at 88 sites in 15 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 88 sites in United States, Russia, Ukraine, Mexico, Bulgaria and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 19 Dec 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs) (time frame: During 104 Weeks (2-years) treatment period). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01914393, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in